title: Prophylactic effect of a peptide vaccine targeting TM4SF5 against colon cancer in a mouse model.
abstract: Expression of transmembrane 4 superfamily member 5 protein (TM4SF5) was implicated in hepatocellular carcinoma (HCC) and colon cancer. Previously, we have shown that immunization with TM4SF5 peptide-CpG-DNA-liposome complex induces production of TM4SF5-specific antibodies and protects mice from HCC progression in an allograft model. Here, we confirmed expression of TM4SF5 in the mouse colon cancer cell line CT-26 and found that anti-TM4SF5 antibody inhibits growth of CT-26 cells. We then immunized mice with TM4SF5 peptide-CpG-DNA-liposome complex and transplanted CT-26 cells to investigate the vaccination effects. Robust production of TM4SF5-specific antibodies was induced by challenge with CT-26 cells and the tumor growth was significantly suppressed in the immunized mice. The peptide vaccine targeting TM4SF5 consequently showed a prophylactic effect against colon cancer development in a mouse model. These results suggest that the peptide vaccine can be potentially applied in humans to treat colon cancer.
authors.affiliation: Center for Medical Science Research, College of Medicine, Hallym University, Gangwon-do 200 702, Republic of Korea.
authors.forename: Sanghoon
authors.initials: S
authors.lastname: Kwon
authors.forename: Young-Eun
authors.initials: YE
authors.lastname: Kim
authors.forename: Dongbum
authors.initials: D
authors.lastname: Kim
authors.forename: Byoung Kwon
authors.initials: BK
authors.lastname: Park
authors.forename: Guang
authors.initials: G
authors.lastname: Wu
authors.forename: Te Ha
authors.initials: TH
authors.lastname: Kim
authors.forename: Song Hee
authors.initials: SH
authors.lastname: Choi
authors.forename: Doo-Sik
authors.initials: DS
authors.lastname: Kim
authors.forename: Hyung-Joo
authors.initials: HJ
authors.lastname: Kwon
authors.forename: Younghee
authors.initials: Y
authors.lastname: Lee
mesh_terms: D000818:Animals; D000906:Antibodies / Q000276:immunology / Q000494:pharmacology; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D003106:Colon / Q000378:metabolism / Q000473:pathology; D003110:Colonic Neoplasms / Q000276:immunology* / Q000401:mortality / Q000517:prevention & control; D004195:Disease Models, Animal; D005434:Flow Cytometry; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007114:Immunization; D007074:Immunoglobulin G / Q000276:immunology / Q000494:pharmacology; D007274:Injections, Intraperitoneal; D008297:Male; D008565:Membrane Proteins / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D010455:Peptides / Q000008:administration & dosage / Q000276:immunology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015996:Survival Rate; D013997:Time Factors; D047368:Tumor Burden / Q000276:immunology
chemical_list: D000906:Antibodies; D019496:Cancer Vaccines; D007074:Immunoglobulin G; D008565:Membrane Proteins; D010455:Peptides; C570858:TM4SF5 protein, mouse